Posted by Michael Wonder on 26 Feb 2020
Vertex announces availability of cystic fibrosis medicine Kalydeco (ivacaftor) in New Zealand
25 February 2020 - Vertex Pharmaceuticals today announced that Kalydeco (ivacaftor) will be available to eligible patients with cystic fibrosis in New Zealand from March 1.
Clinicians are able to apply for patient access using the exceptional circumstances framework set up by the Pharmaceutical Management Agency (PHARMAC).
Vertex’s cystic fibrosis medicines are reimbursed in more than 20 countries around the world including Australia, France, Germany, the Republic of Ireland, Italy, the Netherlands, Sweden, the UK and the U.S.
